Endothelial-to-mesenchymal transition in MPN cardiovascular disease
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-03 — Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.: Preclinical study links JAK2V617F-mutant hematopoiesis to endocardial endothelial dysfunction via upregulated TPO/MPL signaling under cardiometabolic stress, nominating endocardial MPL activation as an upstream trigger of EndMT-associated cardiac microvascular disease reversible by anti-MPL antibody. (novelty: 4)
Open questions
Related
Contributing findings
Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.
03-sep-2026
novelty 4
per-area 4
introduces